Because EMab-17 showed high binding affinity and anti-tumor activity against HCT-15 and HCT-116 cells, we evaluated the ADCC and CDC activities of EMab-17 for CRC cell lines with KRAS p.G13D mutation. This evidence concerns the gene KRAS and neoplasm.